Dynamics of Nigral Iron Accumulation in Parkinson's Disease: From Diagnosis to Late Stage

Is Chelation Therapy a Potential Treatment for Parkinson’s Disease?

(2021) Roberta J. Ward et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Association between Anemia and Risk of Parkinson Disease

(2021) Yao-Chin Wang et al.   BEHAVIOURAL NEUROLOGY

Clinical Progression of Parkinson’s Disease: Insights from the NINDS Common Data Elements

(2020) Mechelle M. Lewis et al.   Journal of Parkinsons Disease

Spatiotemporal changes in substantia nigra neuromelanin content in Parkinson’s disease

(2020) Emma Biondetti et al.   BRAIN

Parkinson’s disease progression in the substantia nigra: location, location, location

(2020) David E Vaillancourt et al.   BRAIN

Reproducible detection of nigral iron deposition in 2 Parkinson's disease cohorts

(2019) Jason Langley et al.   MOVEMENT DISORDERS

Iron in Neurodegeneration – Cause or Consequence?

(2019) Alain Ndayisaba et al.   Frontiers in Neuroscience

Ventral posterior substantia nigra iron increases over 3 years in Parkinson's disease

(2019) Niels Bergsland et al.   MOVEMENT DISORDERS

Quantitative evaluation of iron content in idiopathic rapid eye movement sleep behavior disorder

(2019) Junyan Sun et al.   MOVEMENT DISORDERS

Dopamine promotes cellular iron accumulation and oxidative stress responses in macrophages

(2018) Stefanie Dichtl et al.   BIOCHEMICAL PHARMACOLOGY

Distinct progression pattern of susceptibility MRI in the substantia nigra of Parkinson's patients

(2018) Guangwei Du et al.   MOVEMENT DISORDERS

MEDI+0: Morphology enabled dipole inversion with automatic uniform cerebrospinal fluid zero reference for quantitative susceptibility mapping

(2017) Zhe Liu et al.   MAGNETIC RESONANCE IN MEDICINE

Interactions of iron, dopamine and neuromelanin pathways in brain aging and Parkinson's disease

(2017) Fabio A. Zucca et al.   PROGRESS IN NEUROBIOLOGY

Iron-Restricted Diet Affects Brain Ferritin Levels, Dopamine Metabolism and Cellular Prion Protein in a Region-Specific Manner

(2017) Jessica M. V. Pino et al.   Frontiers in Molecular Neuroscience

Brain iron chelation by deferiprone in a phase 2 randomised double-blinded placebo controlled clinical trial in Parkinson’s disease

(2017) Antonio Martin-Bastida et al.   Scientific Reports

Iron and dopamine: a toxic couple

(2016) Dominic J. Hare et al.   BRAIN

Parkinson's disease-related increase of T2*-weighted hypointensity in substantia nigra pars compacta

(2016) Jason Langley et al.   MOVEMENT DISORDERS

Quantitative Susceptibility Mapping in Parkinson's Disease

(2016) Christian Langkammer et al.   PLoS One

Newly Diagnosed Anemia Increases Risk of Parkinson’s disease: A Population-Based Cohort Study

(2016) Chien Tai Hong et al.   Scientific Reports

Ceruloplasmin activity and iron chelation treatment of patients with Parkinson’s disease

(2015) Guillaume Grolez et al.   BMC Neurology

High nigral iron deposition in LRRK2 and Parkin mutation carriers using R2* relaxometry

(2015) Nadya Pyatigorskaya et al.   MOVEMENT DISORDERS

Quantitative susceptibility mapping of the midbrain in Parkinson's disease

(2015) Guangwei Du et al.   MOVEMENT DISORDERS

MDS clinical diagnostic criteria for Parkinson's disease

(2015) Ronald B. Postuma et al.   MOVEMENT DISORDERS

Neurodegeneration with inflammation is accompanied by accumulation of iron and ferritin in microglia and neurons

(2015) Maj Schneider Thomsen et al.   NEUROBIOLOGY OF DISEASE

The role of iron in brain ageing and neurodegenerative disorders

(2014) Roberta J Ward et al.   LANCET NEUROLOGY

Multi-atlas segmentation of subcortical brain structures via the AutoSeg software pipeline

(2014) Jiahui Wang et al.   Frontiers in Neuroinformatics

Disease duration and the integrity of the nigrostriatal system in Parkinson’s disease

(2013) Jeffrey H. Kordower et al.   BRAIN

Serum Iron Levels and the Risk of Parkinson Disease: A Mendelian Randomization Study

(2013) Irene Pichler et al.   PLOS MEDICINE

Nonlinear formulation of the magnetic field to source relationship for robust quantitative susceptibility mapping

(2012) Tian Liu et al.   MAGNETIC RESONANCE IN MEDICINE

Imaging nigral pathology and clinical progression in Parkinson's disease

(2012) Guangwei Du et al.   MOVEMENT DISORDERS

Quantitative susceptibility mapping (QSM) as a means to measure brain iron? A post mortem validation study

(2012) Christian Langkammer et al.   NEUROIMAGE

Combined R2* and Diffusion Tensor Imaging Changes in the Substantia Nigra in Parkinson's Disease

(2011) Guangwei Du et al.   MOVEMENT DISORDERS

Magnetic resonance imaging markers of Parkinson’s disease nigrostriatal signature

(2010) Patrice Péran et al.   BRAIN

When Do Levodopa Motor Fluctuations First Appear in Parkinson’s Disease

(2010) Fabrizio Stocchi et al.   EUROPEAN NEUROLOGY

The relevance of iron in the pathogenesis of Parkinson’s disease

(2010) Jeswinder Sian-Hülsmann et al.   JOURNAL OF NEUROCHEMISTRY

A reproducible evaluation of ANTs similarity metric performance in brain image registration

(2010) Brian B. Avants et al.   NEUROIMAGE

Quantitative MR Imaging of Brain Iron: A Postmortem Validation Study

(2010) Christian Langkammer et al.   RADIOLOGY

Midbrain iron content in early Parkinson disease: A potential biomarker of disease status

(2008) W. R. W. Martin et al.   NEUROLOGY

Symmetric diffeomorphic image registration with cross-correlation: Evaluating automated labeling of elderly and neurodegenerative brain

(2007) B AVANTS et al.   MEDICAL IMAGE ANALYSIS